Novartis Buys Start-Up Amblyotech To Beat ‘Lazy Eye’ Condition With Gaming Technology
Novartis announced it acquired digital therapeutics company Amblyotech, which uses gaming technology with 3-D glasses to help treat lazy eye.
You may also be interested in...
Developers of new ophthalmic products are thinking outside of the box. A raft of new gene therapies are progressing in the clinic, including a gene therapy paired with biomimetic goggles. Elsewhere, technology players are partnering with traditional biopharmaceutical companies and bringing algorithms, machine learning and microelectronics to bear on eye disorders and disease diagnostics.
Amwell’s CEO Roy Schoenberg foresees a balance between in-patient and digital care, but risks in telemedicine and regulatory issues remain barriers.
The legal battle between Teladoc and Amwell heats up as the post-pandemic future of telehealth remains in question.